{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T15:18:39Z","timestamp":1773242319153,"version":"3.50.1"},"reference-count":70,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Oncology"],"published-print":{"date-parts":[[2003,12]]},"DOI":"10.1016\/s1470-2045(03)01280-4","type":"journal-article","created":{"date-parts":[[2003,12,3]],"date-time":"2003-12-03T06:59:35Z","timestamp":1070434775000},"page":"748-759","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":239,"title":["Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials"],"prefix":"10.1016","volume":"4","author":[{"given":"Thomas K","family":"Eigentler","sequence":"first","affiliation":[]},{"given":"Ulrich M","family":"Caroli","sequence":"additional","affiliation":[]},{"given":"Peter","family":"Radny","sequence":"additional","affiliation":[]},{"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S1470-2045(03)01280-4_bib1","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/sj.bjc.6601320","article-title":"Phase II trial of intralesional therapy with interleukin-2 in soft tissue melanoma metastases","volume":"89","author":"Radny","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/S1470-2045(03)01280-4_bib2","first-page":"219","article-title":"Cutaneous melanoma","volume":"19\u201320","author":"Armstrong","year":"1994","journal-title":"Cancer Surv"},{"key":"10.1016\/S1470-2045(03)01280-4_bib3","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0140-6736(02)09779-9","article-title":"Incidence of and survival from malignant melanoma in Scotland: an epidemiological study","volume":"360","author":"MacKie","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/S1470-2045(03)01280-4_bib4","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/jnci\/84.18.1427","article-title":"Increasing incidence of cutaneous melanoma in Queensland, Australia","volume":"84","author":"MacLennan","year":"1992","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S1470-2045(03)01280-4_bib5","doi-asserted-by":"crossref","first-page":"356","DOI":"10.4065\/72.4.356","article-title":"Malignant melanoma: prognostic indicators","volume":"72","author":"Ahmed","year":"1997","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/S1470-2045(03)01280-4_bib6","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1002\/1097-0142(19950515)75:10<2484::AID-CNCR2820751014>3.0.CO;2-U","article-title":"Primary cutaneous melanoma: identification of prognostic groups and estimation of individual prognosis for 5093 patients","volume":"75","author":"Garbe","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(03)01280-4_bib7","series-title":"Cancer statistics review: 1973\u20131989","first-page":"92","author":"Miller","year":"1992"},{"key":"10.1016\/S1470-2045(03)01280-4_bib8","first-page":"193","article-title":"Prognostic factors in 1,521 melanoma patients with distant metastases","volume":"181","author":"Barth","year":"1995","journal-title":"J Am Coll Surg"},{"key":"10.1016\/S1470-2045(03)01280-4_bib9","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","article-title":"Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(03)01280-4_bib10","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1056\/NEJM199208203270811","article-title":"Disseminated melanoma: is there a new standard therapy?","volume":"327","author":"Guerry","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/S1470-2045(03)01280-4_bib11","first-page":"74","article-title":"Is there a standard for the palliative treatment of melanoma?","volume":"25","author":"Schadendorf","year":"2002","journal-title":"Onkologie"},{"key":"10.1016\/S1470-2045(03)01280-4_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11864-001-0033-5","article-title":"Metastatic melanoma","volume":"2","author":"Sun","year":"2001","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/S1470-2045(03)01280-4_bib13","doi-asserted-by":"crossref","first-page":"657","DOI":"10.7326\/0003-4819-134-8-200104170-00011","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"134","author":"Moher","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/S1470-2045(03)01280-4_bib14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00008390-200202000-00013","article-title":"Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study","volume":"12","author":"Jelic","year":"2002","journal-title":"Melanoma Res"},{"key":"10.1016\/S1470-2045(03)01280-4_bib15","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/1097-0142(197502)35:2<368::AID-CNCR2820350211>3.0.CO;2-C","article-title":"Comparison of the combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and vincristine with two dose schedules of 5-(3,3-dimethyl-1-triazino) imidazole 4-carboxamide (DTIC) in the treatment of disseminated malignant melanoma","volume":"35","author":"Moon","year":"1975","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(03)01280-4_bib16","first-page":"601","article-title":"DTIC (nsc-45388) and combination therapy for melanoma: I, studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065)","volume":"60","author":"Carter","year":"1976","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/S1470-2045(03)01280-4_bib17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1200\/JCO.1984.2.3.164","article-title":"Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma","volume":"2","author":"Luikart","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(03)01280-4_bib18","first-page":"2697","article-title":"[Chemotherapy in advanced malignant melanoma: results of a controlled trial comparing a combination of dacarbazine (DTIC) and detorubicin with dacarbazine alone.]","volume":"58","author":"Chauvergne","year":"1982","journal-title":"Sem Hop"},{"key":"10.1016\/S1470-2045(03)01280-4_bib19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF02985163","article-title":"Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study","volume":"6","author":"Ringborg","year":"1989","journal-title":"Med Oncol Tumor Pharmacother"},{"key":"10.1016\/S1470-2045(03)01280-4_bib20","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","article-title":"Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma","volume":"17","author":"Chapman","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(03)01280-4_bib21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00008390-200104000-00015","article-title":"Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients","volume":"11","author":"Chiarion-Sileni","year":"2001","journal-title":"Melanoma Res"},{"key":"10.1016\/S1470-2045(03)01280-4_bib22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/1097-0142(197701)39:1<5::AID-CNCR2820390103>3.0.CO;2-C","article-title":"Bis chloroethyl nitrosourea, vincristine, dimethyl triazeno imidazole carboxamide and chlorpromazine combination chemotherapy in disseminated malignant melanoma","volume":"39","author":"McKelvey","year":"1977","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(03)01280-4_bib23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/1097-0142(197802)41:2<415::AID-CNCR2820410206>3.0.CO;2-S","article-title":"Combination chemotherapy in metastatic malignant melanoma: a randomized study of three DTIC-containing combination","volume":"41","author":"Wittes","year":"1978","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(03)01280-4_bib24","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/S0959-8049(98)00068-9","article-title":"Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma: a randomised phase III trial","volume":"34","author":"Jungnelius","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1016\/S1470-2045(03)01280-4_bib25","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"Middleton","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(03)01280-4_bib26","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1054\/bjoc.1999.1056","article-title":"A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma","volume":"82","author":"Middleton","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/S1470-2045(03)01280-4_bib27","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1056\/NEJM199208203270803","article-title":"Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen","volume":"327","author":"Cocconi","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/S1470-2045(03)01280-4_bib28","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1200\/JCO.1996.14.7.2083","article-title":"Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma","volume":"14","author":"Rusthoven","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(03)01280-4_bib29","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.1999.17.6.1884","article-title":"Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma","volume":"17","author":"Creagan","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(03)01280-4_bib30","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9<1979::AID-CNCR15>3.0.CO;2-G","article-title":"A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma","volume":"85","author":"Agarwala","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(03)01280-4_bib31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00008390-200302000-00012","article-title":"Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen, or vindesine plus tamoxifen: a prospective randomized study","volume":"13","author":"Cocconi","year":"2003","journal-title":"Melanoma Res"},{"key":"10.1016\/S1470-2045(03)01280-4_bib32","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/1097-0142(19800801)46:3<475::AID-CNCR2820460310>3.0.CO;2-1","article-title":"A trial of imidazole carboxamide and corynebacterium parvum in disseminated melanoma: clinical and immunologic results","volume":"46","author":"Clunie","year":"1980","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(03)01280-4_bib33","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/mpo.2950100305","article-title":"Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: a Southwest Oncology Group study","volume":"10","author":"Costanzi","year":"1982","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/S1470-2045(03)01280-4_bib34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/030089168407000107","article-title":"Controlled study with imidazole carboxamide (DTIC), DTIC + bacillus Calmette-Guerin (BCG), and DTIC + corynebacterium parvum in advanced malignant melanoma","volume":"70","author":"Veronesi","year":"1984","journal-title":"Tumori"},{"key":"10.1016\/S1470-2045(03)01280-4_bib35","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/1097-0142(19840215)53:4<833::AID-CNCR2820530402>3.0.CO;2-#","article-title":"Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma: a Southwest Oncology Group study","volume":"53","author":"Costanzi","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(03)01280-4_bib36","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF00686489","article-title":"A randomised phase II study of carmustine alone or in combination with tumour necrosis factor in patients with advanced melanoma","volume":"30","author":"Jones","year":"1992","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/S1470-2045(03)01280-4_bib37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.2002.20.1.125","article-title":"Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma","volume":"20","author":"Agarwala","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(03)01280-4_bib38","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1200\/JCO.1991.9.8.1403","article-title":"Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma","volume":"9","author":"Falkson","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(03)01280-4_bib39","first-page":"133","article-title":"Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial","volume":"3","author":"Thomson","year":"1993","journal-title":"Melanoma Res"},{"key":"10.1016\/S1470-2045(03)01280-4_bib40","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1200\/JCO.1994.12.4.806","article-title":"Multicenter randomized trial of dacarbazine alone or in ombination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma","volume":"12","author":"Bajetta","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(03)01280-4_bib41","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF01571406","article-title":"Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma","volume":"12","author":"Falkson","year":"1995","journal-title":"Med Oncol"},{"key":"10.1016\/S1470-2045(03)01280-4_bib42","first-page":"458","article-title":"Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma","volume":"13","author":"Young","year":"2001","journal-title":"Clin Oncol"},{"key":"10.1016\/S1470-2045(03)01280-4_bib43","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1200\/JCO.1998.16.5.1743","volume":"16","author":"Falkson","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(03)01280-4_bib44","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1200\/JCO.1993.11.10.1969","article-title":"Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma","volume":"11","author":"Sparano","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(03)01280-4_bib45","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1060::AID-CNCR8>3.0.CO;2-2","article-title":"Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study","volume":"85","author":"Dorval","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(03)01280-4_bib46","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00008390-199910000-00010","article-title":"Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma","volume":"9","author":"Sertoli","year":"1999","journal-title":"Melanoma Res"},{"key":"10.1016\/S1470-2045(03)01280-4_bib47","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1054\/bjoc.2001.1731","article-title":"Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)","volume":"84","author":"Hauschild","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/S1470-2045(03)01280-4_bib48","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2001.19.13.3194","article-title":"Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials","volume":"19","author":"Flaherty","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(03)01280-4_bib49","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/1097-0142(19891115)64:10<2024::AID-CNCR2820641010>3.0.CO;2-V","article-title":"A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma","volume":"64","author":"Legha","year":"1989","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(03)01280-4_bib50","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/oxfordjournals.annonc.a010762","article-title":"Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha","volume":"7","author":"Legha","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(03)01280-4_bib51","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1200\/JCO.2002.07.044","article-title":"Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial","volume":"20","author":"Eton","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(03)01280-4_bib52","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/bjc.1998.214","article-title":"Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma","volume":"77","author":"Johnston","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/S1470-2045(03)01280-4_bib53","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/sj.bjc.6600043","article-title":"Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)","volume":"86","author":"Atzpodien","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/S1470-2045(03)01280-4_bib54","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.1999.17.3.968","article-title":"Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b","volume":"17","author":"Rosenberg","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(03)01280-4_bib55","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.2002.20.6.1600","article-title":"Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial","volume":"20","author":"Ridolfi","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(03)01280-4_bib56","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1200\/JCO.1997.15.7.2579","article-title":"Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group","volume":"15","author":"Keilholz","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(03)01280-4_bib57","series-title":"The Cochrane Library, Issue 2","article-title":"Systematic treatments for metastatic cutaneous melanoma (Cochrane Review)","author":"Crosby","year":"2003"},{"key":"10.1016\/S1470-2045(03)01280-4_bib58","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(03)01280-4_bib59","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(97)12445-X","article-title":"Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1\u00b75 mm without clinically detectable node metastases","volume":"351","author":"Grob","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/S1470-2045(03)01280-4_bib60","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1200\/JCO.1999.17.2.651","article-title":"Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma","volume":"17","author":"Richards","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(03)01280-4_bib61","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/0959-8049(94)00459-5","article-title":"Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen","volume":"31A","author":"Atzpodien","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1016\/S1470-2045(03)01280-4_bib62","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00008390-200102000-00009","article-title":"Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials","volume":"11","author":"Huncharek","year":"2001","journal-title":"Melanoma Res"},{"key":"10.1016\/S1470-2045(03)01280-4_bib63","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/jnci\/94.11.805","article-title":"Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?","volume":"94","author":"Parmiani","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S1470-2045(03)01280-4_bib64","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1084\/jem.190.11.1669","article-title":"Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma","volume":"190","author":"Thurner","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/S1470-2045(03)01280-4_bib65","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1084\/jem.20012100","article-title":"Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells","volume":"195","author":"Schuler-Thurner","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/S1470-2045(03)01280-4_bib66","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nm0398-328","article-title":"Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells","volume":"4","author":"Nestle","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/S1470-2045(03)01280-4_bib67","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nm0298-232","article-title":"Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice","volume":"4","author":"Jansen","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/S1470-2045(03)01280-4_bib68","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/labinvest.3780375","article-title":"RGD peptides and monoclonal antibodies, antagonists of alpha(v)-integrin, enter the cells by independent endocytic pathways","volume":"81","author":"Castel","year":"2001","journal-title":"Lab Invest"},{"key":"10.1016\/S1470-2045(03)01280-4_bib69","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-1-4615-4221-6_14","article-title":"Targeting integrins alpha v beta 3 and alpha v beta 5 for blocking tumor-induced angiogenesis","volume":"476","author":"Kumar","year":"2000","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/S1470-2045(03)01280-4_bib70","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/BF03032599","article-title":"The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis","volume":"7","author":"John","year":"2001","journal-title":"Pathol Oncol Res"}],"container-title":["The Lancet Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204503012804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204503012804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T05:50:08Z","timestamp":1761457808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204503012804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":70,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["S1470204503012804"],"URL":"https:\/\/doi.org\/10.1016\/s1470-2045(03)01280-4","relation":{},"ISSN":["1470-2045"],"issn-type":[{"value":"1470-2045","type":"print"}],"subject":[],"published":{"date-parts":[[2003,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials","name":"articletitle","label":"Article Title"},{"value":"The Lancet Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(03)01280-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}